Phase 2 Metabolic Benefits Beyond weight loss, retatrutide improved cardiometabolic markers: Blood pressure: Systolic BP decreased 7.4 mmHg (12mg dose) Triglycerides: Reduced 27% from baseline Fasting glucose: Decreased 13.8 mg/dL HbA1c: Reduced 0.4% (in participants without diabetes) TRIUMPH-4: First Phase 3 Results (December 2025) TRIUMPH-4 was the first Phase 3 trial to report
Recent insights into the role of macrophages in acute gout
Parkinsons disease: the syndrome, the pathogenesis and pathophysiology
This guide covers how to structure the six-hour peri-workout window, the protein and carbohydrate targets that support recovery, and the exception cases where timing does actually matter
If you are comparing treatment options, our guide to semaglutide side effects and management tips may be helpful
Combination with GHRH Analogues Both Ipamorelin and GHRP-6 are studied in combination with GHRH analogues (Sermorelin, CJC-1295), producing synergistic GH release through dual receptor pathway activation
